ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0022

Impact of COVID-19-Associated AKI on Subsequent Development of CKD

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Mohamed, Muner, Ochsner Medical Center - New Orleans, New Orleans, Louisiana, United States
  • Dwal, Ashraf, Ochsner Medical Center - New Orleans, New Orleans, Louisiana, United States
  • Velez, Juan Carlos Q., Ochsner Medical Center - New Orleans, New Orleans, Louisiana, United States

There is paucity of data about post-hospital discharge kidney-related outcomes in individuals with COVID-19-associated acute kidney injury (CoV-AKI) during the pandemic. We hypothesized that patients who survive a hospital admission due to COVID-19 and AKI are at risk for acquiring residual chronic kidney disease (CKD) thereafter.


We conducted a retrospective observational study examining records of patients hospitalized at Ochsner Medical Center over a 3-month period (March-May 2020) with COVID-19 and diagnosis of AKI by KDIGO. We examined the rate of full recovery of AKI (serum creatinine value back to within 10% of baseline or < 1.2 mg/dL) at 9 months post-hospital discharge. Factors associated with recovery were assessed.


Among 916 admissions due to COVID-19 within the study [220 (24%) to an intensive care unit], there were 226 (26%) cases of AKI, 98 of them (43%) with AKI-requiring dialysis (AKI-RRT). Patients with CoV-AKI had a median age of 67 (34-99) and 58% were men. Self-identified black race accounted for 65% of the cohort. Among those with CoV-AKI, there were 111 in-hospital deaths (49%). Of 115 patients with CoV-AKI who were discharged alive, 9-month follow-up data were retrieved in 97 (missing data in 18). Full recovery of kidney function was achieved by 76 (78%). Among those who progressed to residual CKD, 11 (11%) patients were declared to have end-stage kidney disease (ESKD) requiring dialysis. Baseline CKD stages 3-5 was associated with lower rate of full renal recovery [23/76 (30%) vs. 14/23 (61%); RR: 2.01, p=0.004)].


Full recovery from CoV-AKI was observed in ¾ of those who remain alive post-hospital discharge. About 1/10th of patients with CoV-AKI reached ESKD at intermediate-term follow-up. Preexisting CKD is associated with lower rate of recovery in CoV-AKI. These data do not seem to suggest that CoV-AKI is associated with greater risk for development of CKD compared to other forms of in-hospital AKI.